Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 6/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7687480 | 0.83 | PRKCI (0.42) | PRKCIMAPTSMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL7681529 | 0.83 | GAA (0.40) | PRKCIHPGDHTTMAPTSMN1; SMN2 | |
| SCHEMBL7688013 | 0.81 | SLC29A1 (0.43) | PRKCIMAPTHSD17B10KMT2AKDM4E | |
| SCHEMBL7686103 | 0.80 | LCK (0.36) | HTTMAPTSMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL7681398 | 0.80 | PRKCI (0.40) | PRKCIHTTMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL7678778 | 0.80 | PRKCI (0.41) | PRKCIMAPTALDH1A1RAB9AKMT2A | |
| SCHEMBL7682019 | 0.79 | PRKCI (0.38) | PRKCIHPGDHTTMAPTSMN1; SMN2 | |
| SCHEMBL7685780 | 0.79 | PRKCI (0.41) | PRKCIMAPTALDH1A1RAB9AKMT2A | |
| SCHEMBL7685868 | 0.79 | PRKCI (0.41) | PRKCIMAPTALDH1A1RAB9AKMT2A | |
| SCHEMBL7688049 | 0.79 | PRKCI (0.41) | PRKCIMAPTALDH1A1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6339089-B2 | ANTIHYPOXIC AGENTS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; VASOCONSTRICTION; REDUCES BLOOD PARTIAL PRESSURE OF CARBON DIOXIDE; RESPIRATORY DISORDERS; UNDER OXYGEN INHALATION TREATMENT | FUJIREBIO INC. (JP) | 2002-01-15 | — | — | US | disclosed |
| US-20010006969-A1 | PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME | FUJIREBIO INC. (FUJIREBIO KABUSHIKI KAISHA) (JP) | 2001-07-05 | — | — | US | disclosed |
| EP-0899263-A2 | Fused pyrimidine derivatives and medicaments thereof for a blood oxygen partial pressure amelioration | Fujirebio Inc. (JP) | 1999-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010006969-A1 | PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME | CYP11B2, CYP11B1, OAT | PRKCI 2876/4885HPGD 419/4885HTT 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.